Chat
Malignancy Risk Assessment, Pelvic Mass, OVA1 Plus
3002309
Copy Utility
Ordering Recommendation
Assess risk of ovarian cancer in women who present with an adnexal mass.
Mnemonic
OVA1 PLUS
Methodology
Electrochemiluminescent Immunoassay (ECLIA)/Fixed-Rate-Time Nephelometry
Performed
Varies
Reported
4-8 days
N/A
New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation
Collect
Serum Separator Tube (SST).
Specimen Preparation
Transfer 2.2 mL serum to an ARUP Standard Transport Tube. (Min: 1.1 mL)
Storage/Transport Temperature
Frozen. Also acceptable: Refrigerated.
Unacceptable Conditions
Remarks
Stability
Ambient: Unacceptable; Refrigerated: 8 days; Frozen: 9 weeks
Reference Interval
By Report
Interpretive Data
No compliance statements are in use for this test.
Note
OVA1 Biomarkers: CA-125 II, Apoliproprotein A1 (Apo A-1), Beta-2 Microglobulin (B2M), Transferrin, and Prealbumin.
OVERA Biomarkers: Apolipoprotein A1 (Apo A-1), HE4 (Human Epididymis protein 4), CA-125 II, FSH (Follicle Stimulating Hormone), and Transferrin.
Hotline History
Hotline History
Date of Change
Test Name Change
Methodology
Performance/Reported Schedule
Specimen Requirements
Reference Interval
Interpretive Data
Note
CPT Code
Component Change
Other Interface Change
New Test
Inactive
N/A
CPT Codes
81503
Components
| Component Test Code* | Component Chart Name | LOINC |
|---|---|---|
| 3002310 | EER Malignancy Assessment, OVA1 Plus | |
| 3002311 | Malignancy Assessment, Menopausal Status | |
| 3002312 | Malignancy Assessment, CA 125 II | |
| 3002313 | Malignancy Assessment, OVA1 Score | |
| 3002615 | Malignancy Assessment, OVERA Score |
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
Malignancy Risk Assessment, Pelvic Mass, OVA1 Plus
ASPiRA Labs, Inc
Feedback
